Boehringer Ingelheim and CDR-Life Expand Collaboration
Boehringer Ingelheim and CDR-Life, Inc. announced a global licensing agreement for CDR111, an antibody-based trispecific M-gager.
The agreement aims to develop CDR111 for autoimmune diseases, targeting and depleting B cells to achieve immune system reset.
- CDR111 is designed to selectively target dysregulated B cells, which play a central role in autoimmune and inflammatory conditions.
- Conditions that may be treated with this approach include lupus, multiple sclerosis, and certain forms of arthritis.
The agreement builds on the companies’ successful collaboration on an investigational antibody fragment.
Author's summary: Boehringer Ingelheim and CDR-Life collaborate on autoimmune disease treatment.